Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene

In a real-world analysis of brexucabtagene autoleucel (brexu-cel) recipients with relapsed/refractory B-ALL (n = 278), lack of response to prior blinatumomab correlates with significantly worse post CAR-T outcomes.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-02-05
DOI
https://doi.org/10.1182/blood.2025031734
Citations
1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
24.20
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene

Jozal Moore, Rawan Faramand, Joshua Sasine, Christian Gordillo et al.
1 citations
Blood
CAR-T cell therapy research
24.20
article

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene

Jozal Moore, Rawan Faramand, Joshua Sasine, Christian Gordillo, Fevzi Yalniz, George Yaghmour, Navneet S. Majhail, Marlise Rachael Luskin, TIMOTHY E. O'CONNOR, Roshini Pradeep, Omer Jamy, Stephen A. Strickland, Caspian Oliai, Jessica Leonard, Tamer Adel Othman, Vivian Irizarry Gatell, Eunice S. Wang, C F Lee, Olalekan O. Oluwole, Gregory W. Roloff, Razan Mohty, Noam E. Kopmar, B. D. Shah, Muthu Sendhil Kumaran, Caitlin Guzowski, Karamjeet Sandhu, M. Ulrickson, Ryan D. Cassaday, Sean Tracy, Miller Kk, Kaitlyn C. Dykes, Anjali S. Advani, Hrishikesh K. Srinagesh, Yannis K. Valtis, Michael Daunov, Virginia Tan, Ross McCauley, Vishal Gupta, L Hill, Katherine C. Sutherland, Aaron Logan, Jacob Boccucci, Lori Muffly, Talal Hilal, Chenyu Lin, Melhem M Solh, Vamsi Kota, Kristen M O'Dwyer, Rasmus T. Hoeg, Kevin Tang, Ibrahim Aldoss, Stephanie B. Tsai, Veronika Bachanova, Evan C. Chen, Amy Zhang, Clayton Jackson, Matthew P Connor, Jae H Park, Michael R Grunwald, Bhagirathbhai Dholaria, Marc S. Schwartz, Kenneth Byrd, Wendy A Stock, Silvina Odstrcil Bobillo, Sumithira Vasu
article en
1 citations

Abstract

In a real-world analysis of brexucabtagene autoleucel (brexu-cel) recipients with relapsed/refractory B-ALL (n = 278), lack of response to prior blinatumomab correlates with significantly worse post CAR-T outcomes.

Blood
Northside Hospital (US), University of Southern California (US), Cedars-Sinai Medical Center (US), Roswell Park Comprehensive Cancer Center (US), City Of Hope National Medical Center (US), Loyola University Medical Center (US), Cleveland Clinic (US), Memorial Sloan Kettering Cancer Center (US), University of Kentucky (US), University of Kansas (US), University of California, Los Angeles (US), Oregon Health & Science University (US), Duke University (US), Palo Alto University (US), University of California, San Francisco (US), Baylor College of Medicine (US), University of Washington (US), University of Utah (US), University Hospitals of Cleveland (US), Columbia University Irving Medical Center (US), University of Arkansas Medical Center (US), UCLA Health (US), Hospital of the University of Pennsylvania (US), University of Minnesota System (US), Huntsman Cancer Institute (US), University of Rochester Medical Center (US), Moffitt Cancer Center (US), University of Alabama at Birmingham (US), University of California San Diego (US), University of Chicago (US), Augusta University Health (US), Centennial Medical Center (US), Fred Hutch Cancer Center (US), Southwestern Medical Center (US), Levine Cancer Institute (US), Children’s Hospital at TriStar Centennial (US), Sarah Cannon (US), City of Hope (US), HOPE Clinic (US), Dana-Farber Cancer Institute (US), Mayo Clinic Hospital (US), Banner MD Anderson Cancer Center, University of Colorado Anschutz Medical Campus (US), The Ohio State University (US), University of Rochester (US), University of Pennsylvania (US), University of California, Davis (US), The University of Texas Southwestern Medical Center (US), Vanderbilt University Medical Center (US), Stanford University (US)
No poverty
Openalex Percentile: Top 1%
CAR-T cell therapy research
24.20
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.